Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Drilon

Showing results (121-130 of 268) with videos related to

Pageof 27
Sort By:
Molecular Oncology|March 26, 2022
Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinibRafal Dziadziuszko, Tiffany Hung, Kun Wang, et al.
JCO Precision Oncology|January 27, 2022
Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung CancersAlexander Drilon, Daniel S W Tan, Ulrik N Lassen, et al.
Molecular Oncology|November 6, 2025
Dual targeting of RET and SRC synergizes in RET fusion-positive cancer cellsJuhyeon Son, Lily L Remsing Rix, Bin Fang, et al.
JCO Precision Oncology|June 4, 2019
Acquired <i>MET</i> Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung CancerKen Suzawa, Michael Offin, Adam J Schoenfeld, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2022
Bioinformatically Expanded Next-Generation Sequencing Analysis Optimizes Identification of Therapeutically Relevant MET Copy Number Alterations in >50,000 TumorsJames P Solomon, Soo-Ryum Yang, Noura J Choudhury, et al.
Oral Oncology|January 7, 2023
Precision oncology using organoids of a secretory carcinoma of the salivary gland treated with TRK-inhibitorsGerben Lassche, Adriana C H van Engen-van Grunsven, Onno van Hooij, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2018
Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with <i>EGFR</i>-Mutant Lung CancersMichael Offin, Hira Rizvi, Megan Tenet, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 20, 2022
Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001Caroline E McCoach, Christian Rolfo, Alexander Drilon, et al.
The Lancet. Oncology|November 10, 2016
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trialAlexander Drilon, Natasha Rekhtman, Maria Arcila, et al.
JCO Precision Oncology|May 6, 2026
<i>NTRK</i> Gene Fusions: A Compendium of Fusion Partners and Tumor TypesSoo-Ryum Yang, Matteo Repetto, Erin R Rudzinski, et al.
Pageof 27

Showing results (121-130 of 268) with videos related to

Sort By:
Pageof 27
Molecular Oncology|March 26, 2022
Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinibRafal Dziadziuszko, Tiffany Hung, Kun Wang, et al.
JCO Precision Oncology|January 27, 2022
Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung CancersAlexander Drilon, Daniel S W Tan, Ulrik N Lassen, et al.
Molecular Oncology|November 6, 2025
Dual targeting of RET and SRC synergizes in RET fusion-positive cancer cellsJuhyeon Son, Lily L Remsing Rix, Bin Fang, et al.
JCO Precision Oncology|June 4, 2019
Acquired <i>MET</i> Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung CancerKen Suzawa, Michael Offin, Adam J Schoenfeld, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2022
Bioinformatically Expanded Next-Generation Sequencing Analysis Optimizes Identification of Therapeutically Relevant MET Copy Number Alterations in >50,000 TumorsJames P Solomon, Soo-Ryum Yang, Noura J Choudhury, et al.
Oral Oncology|January 7, 2023
Precision oncology using organoids of a secretory carcinoma of the salivary gland treated with TRK-inhibitorsGerben Lassche, Adriana C H van Engen-van Grunsven, Onno van Hooij, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2018
Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with <i>EGFR</i>-Mutant Lung CancersMichael Offin, Hira Rizvi, Megan Tenet, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 20, 2022
Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001Caroline E McCoach, Christian Rolfo, Alexander Drilon, et al.
The Lancet. Oncology|November 10, 2016
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trialAlexander Drilon, Natasha Rekhtman, Maria Arcila, et al.
JCO Precision Oncology|May 6, 2026
<i>NTRK</i> Gene Fusions: A Compendium of Fusion Partners and Tumor TypesSoo-Ryum Yang, Matteo Repetto, Erin R Rudzinski, et al.
Pageof 27